Business
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar MarketGlen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received a six-figure development milestone payment from Adovate, LLC,
About this update from Adial Pharmaceuticals, Inc
[{"type":"image","alt":"Adial Pharmaceuticals, Inc","displaySize":"","headline":null,"caption":"Adial Pharmaceuticals, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fKhTAZbrVcry7QkXYXjJNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8","width":282,"height":123}},"lazy":false},{"type":"text","content":"Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market","length":136,"tagName":"p"},{"type":"text","content":"Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received a six-figure development milestone payment from Adovate, LLC, following the commencement of a Phase 1 clinical trial evaluating Adovate’s lead compound for asthma, ADO-5030.","length":475,"tagName":"p"},{"type":"text","content":"This milestone payment follows Adovate’s exercise of its option to acquire the assets and business of Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, as previously disclosed. The ongoing Phase 1 study is a Single Ascending Dose (SAD) clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of Adovate’s novel adenosine receptor antagonist in healthy volunteers. The compound is being developed as a potential first-line therapy for asthma, a large and underserved global market with substantial unmet medical needs, with a differentiated mechanism of action and the potential to shift the treatment paradigm for asthma patients globally.","length":685,"tagName":"p"},{"type":"text","content":"Cary Claiborne, CEO of Adial Pharmaceuticals, said “This milestone highlights the value of our strategic decision to monetize the Purnovate assets while retaining meaningful upside. The structure of the deal provides non-dilutive capital and a strong equity position, allowing us to focus our resources on advancing AD04 while continuing to benefit from the prog...